VERU INC. (The Female Health Company) - 10-K Summary
Business Context and Reporting Period
Company: The Female Health Company (VERU INC.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2010
Business Overview: The Company manufactures, markets, and sells the FC2 female condom, the only FDA-approved product under a woman's control providing dual protection against unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. In October 2009, the Company completed the transition from its first-generation product (FC1) to the second-generation product (FC2). FC2 is manufactured in Malaysia and India, whereas FC1 was manufactured in the U.K. The Company's primary customers are global public health sector agencies, including UNFPA and USAID.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Net Revenues | $22,221,955 | $27,543,341 |
| Gross Profit | $12,924,819 | $13,517,818 |
| Gross Margin | 58% | 49% |
| Operating Income | $4,349,160 | $4,718,014 |
| Net Income (Attributable to Common Stockholders) | $6,737,078 | $6,455,662 |
| Diluted EPS | $0.24 | $0.24 |
| Cash Flow from Operations | $3,991,855 | $5,747,114 |
| Working Capital | $9.9 million | $9.2 million |
| Stockholders' Equity | $16.1 million | $13.0 million |
| Debt | No outstanding borrowings under revolving credit facilities | No outstanding borrowings |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 19% to $22.2 million, primarily due to the transition to FC2, which is sold at a price approximately 30% lower than FC1. Unit sales were 3% lower than fiscal 2009 due to delays in receiving two large orders in the third quarter.
- Margin Expansion: Despite lower revenues, gross margin increased from 49% to 58%. This was driven by the shift in product mix to 98% FC2 (compared to 51% in 2009), which has a lower cost of production.
- Restructuring Costs: The Company incurred a one-time charge of $1.9 million in fiscal 2010 related to exiting the lease of its former U.K. manufacturing facility. In fiscal 2009, a $1.5 million charge was incurred for restructuring costs related to the cessation of FC1 manufacturing and employee redundancies.
- Dividends: The Company initiated a quarterly cash dividend policy in January 2010, paying a total of approximately $4.1 million in dividends during fiscal 2010. No dividends were paid in fiscal 2009.
- Foreign Currency: The Company recorded a foreign currency transaction loss of $154,196 in 2010, compared to a gain of $276,113 in 2009. This change reflects the adoption of the U.S. dollar as the functional currency for U.K. and Malaysia subsidiaries effective October 1, 2009.
Guidance, Outlook, and Risks
Outlook and Commentary: Management believes the current cash position is adequate to fund operations for the next 12 months. The Company expects to derive the vast majority of future revenues from the FC2 female condom. The Company submitted a bid for 10 million FC2 units for the Brazilian Government in late 2010. The Company has a backlog of approximately $6.4 million as of December 1, 2010.
Risks and Contingencies:
- Single Product Reliance: The Company relies almost exclusively on the FC2 female condom. Demand is not yet fully known globally.
- Customer Concentration: Significant customers include UNFPA (37% of unit sales) and John Snow, Inc. (33% of unit sales). No other single customer accounted for more than 10% of unit sales.
- Regulatory Risk: FC2 is a Class III medical device subject to FDA regulation. Failure to comply with regulations could result in fines, recalls, or withdrawal of approval.
- Competition: Male condoms are less expensive and have greater brand recognition. Competitors with greater financial resources may develop competing female condoms.
- Liquidity: While currently liquid, the Company may not have sufficient cash flows to continue paying dividends in the future. Dividends are at the discretion of the Board.
Key Facts for Investor Verification
- Product Transition: Verify the success of the FC2 market penetration and the stability of pricing in the public health sector, given the 30% price reduction from FC1.
- Customer Concentration: Monitor the dependency on UNFPA and USAID (via John Snow, Inc.), which together accounted for 70% of unit sales in fiscal 2010.
- Dividend Sustainability: Assess whether operating cash flows can sustain the new quarterly dividend policy ($0.05 per share) alongside capital expenditures and restructuring obligations.
- Backlog: Confirm the conversion of the $6.4 million backlog into recognized revenue in fiscal 2011.
- Regulatory Compliance: Monitor FDA inspection results and any potential changes in regulatory requirements for Class III medical devices.